本文選題：子宮頸腺癌 + 預(yù)后因素��； 參考：《遼寧中醫(yī)藥大學(xué)》2017年碩士論文

【摘要】：目的:分析可能影響子宮頸腺癌預(yù)后的相關(guān)因素,討論中藥苦參相關(guān)制劑輔助治療對子宮頸腺癌預(yù)后的影響,為子宮頸腺癌患者的預(yù)后及中西醫(yī)治療提供理論依據(jù)。材料與方法:回顧性分析2014年1月至2016年12月于遼寧省腫瘤醫(yī)院婦科住院治療的178例經(jīng)病理診斷為子宮頸腺癌的患者,其中拒絕治療5例,共173例被納入研究。按病例納入標(biāo)準(zhǔn)搜集患者的相關(guān)臨床資料。使用SPSS17.0統(tǒng)計軟件對收集的資料進(jìn)行分析和處理,使用壽命表法分別算出其1年、2年和3年生存率,影響子宮頸腺癌預(yù)后的相關(guān)因素分析使用Kaplan-Meier法,并用Log-rank進(jìn)行差異性檢驗(yàn),多因素分析采用Cox回歸模型進(jìn)行數(shù)據(jù)處理。P0.05認(rèn)為差異有統(tǒng)計學(xué)意義。結(jié)果:1.納入研究的子宮頸腺癌患者復(fù)發(fā)率為2.31%,轉(zhuǎn)移率為9.83%。1年生存率為91%,2年生存率為76%,3年生存率為73%。2.臨床分期、肌層浸潤程度和有無淋巴結(jié)受累是子宮頸腺癌預(yù)后的相關(guān)影響因素(P0.05),臨床分期和有無淋巴結(jié)受累是其獨(dú)立的預(yù)后影響因素(P0.05)。3.子宮頸腺癌的FIGO分期中,I期的3年生存率為92%、II期的3年生存率為74%、III期的3年生存率為36%,3年總生存率為81%。4.是否使用中藥苦參相關(guān)制劑輔助治療不是子宮頸腺癌預(yù)后的相關(guān)影響因素(P0.05),但從生存率可以看出,使用中藥苦參相關(guān)制劑輔助治療的子宮頸腺癌患者的生存質(zhì)量情況明顯優(yōu)于未使用的。結(jié)論:1.臨床分期、肌層浸潤程度和有無淋巴結(jié)受累是子宮頸腺癌預(yù)后的相關(guān)影響因素,且臨床分期和有無淋巴結(jié)受累是其獨(dú)立的預(yù)后影響因素。2.采用中藥苦參相關(guān)制劑輔助治療不是子宮頸腺癌預(yù)后的相關(guān)影響因素,但可以提高子宮頸腺癌患者的生存率,改善預(yù)后。
[Abstract]:Objective: to analyze the related factors that may affect the prognosis of cervical adenocarcinoma, and discuss the influence of the auxiliary therapy of traditional Chinese medicine Sophora flavescens on the prognosis of cervical adenocarcinoma, so as to provide a theoretical basis for the prognosis of cervical adenocarcinoma patients and the treatment of traditional Chinese medicine and western medicine.Materials and methods: 178 cases of cervical adenocarcinoma diagnosed by pathology from January 2014 to December 2016 in Liaoning Cancer Hospital were retrospectively analyzed. Among them, 5 cases were refused treatment and 173 cases were included in the study.Collect the relevant clinical data according to the standard of case inclusion.The data collected were analyzed and processed by SPSS17.0 software. The 1 year, 2 year and 3 year survival rates were calculated by using life table method. Kaplan-Meier method was used to analyze the related factors affecting the prognosis of cervical adenocarcinoma and Log-rank was used to test the difference.Multivariate analysis using Cox regression model for data processing. P05 that the difference was statistically significant.The result is 1: 1.The recurrence rate was 2.31, the metastasis rate was 9.83.1 year survival rate was 91, the 2-year survival rate was 76, and the 3-year survival rate was 73.2.Clinical stage, myometrial invasion degree and lymph node involvement were related factors of prognosis of cervical adenocarcinoma. Clinical stage and lymph node involvement were independent prognostic factors.In FIGO staging of cervical adenocarcinoma, the 3-year survival rate of stage I was 92and the 3-year survival rate of stage II was 74.The 3-year survival rate of stage III was 36, and the overall survival rate of 3-year was 81.4.Whether or not to use the traditional Chinese medicine Sophora flavescens associated with adjuvant treatment is not a related factor for the prognosis of cervical adenocarcinoma P0.05, but from the survival rate can be seen,The quality of life (QOL) of patients with cervical adenocarcinoma treated with Sophora flavescens was significantly better than that of untreated patients.Conclusion 1.The clinical stage, the degree of myometrial invasion and lymph node involvement were related factors of prognosis of cervical adenocarcinoma, and clinical stage and lymph node involvement were independent prognostic factors.The adjuvant therapy of Sophora flavescens is not a related factor in the prognosis of cervical adenocarcinoma, but it can improve the survival rate and prognosis of patients with cervical adenocarcinoma.
【學(xué)位授予單位】：遼寧中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R737.33

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 邱嘯臣;張博;李元新;;慢性放射性腸炎的研究進(jìn)展[J];大連醫(yī)科大學(xué)學(xué)報;2015年03期

2 王昀;馬亞琪;劉愛軍;Kurman RJ;Carcangiu ML;Herrington CS;;WHO(2014)陰道、外陰腫瘤組織學(xué)分類[J];診斷病理學(xué)雜志;2014年12期

3 周志華;;TP和PF方案同步放化療治療中晚期宮頸癌的療效比較[J];中國醫(yī)藥指南;2014年20期

4 蔣小蘭;劉甲炎;;134例宮頸癌手術(shù)治療病例分析[J];中外醫(yī)學(xué)研究;2014年13期

5 高孟翠;王玉鳳;;采用腹腔鏡下廣泛子宮切除及盆腔淋巴結(jié)清掃術(shù)治療早期宮頸癌安全性及有效性研究[J];社區(qū)醫(yī)學(xué)雜志;2014年08期

6 王s，

本文編號：1743855